bumetanide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
diuretics, piretanide derivatives 427 28395-03-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • bumetanide
  • bumethanide
  • bufenox
A sulfamyl diuretic.
  • Molecular weight: 364.42
  • Formula: C17H20N2O5S
  • CLOGP: 3.07
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 3
  • TPSA: 118.72
  • ALOGS: -4.15
  • ROTB: 8
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 mg O
1 mg P
1 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 45 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.46 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 90 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.16 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.03 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Feb. 28, 1983 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 227.09 13.22 406 24744 227652 50352322
Cardiac failure congestive 219.65 13.22 239 24911 84143 50495831
Fluid retention 195.82 13.22 178 24972 50471 50529503
Hypervolaemia 190.28 13.22 132 25018 25367 50554607
Dyspnoea 171.83 13.22 628 24522 546980 50032994
Pulmonary arterial hypertension 128.19 13.22 95 25055 20224 50559750
Right ventricular failure 122.60 13.22 84 25066 15809 50564165
Pulmonary hypertension 110.98 13.22 108 25042 33309 50546665
Drug ineffective 109.74 13.22 149 25001 819184 49760790
Renal failure 102.14 13.22 187 24963 106446 50473528
Oedema peripheral 98.37 13.22 232 24918 157729 50422245
Body tinea 92.90 13.22 32 25118 1295 50578679
Oedema 84.15 13.22 136 25014 70045 50509929
Cardiac failure 83.98 13.22 142 25008 75898 50504076
International normalised ratio increased 80.21 13.22 103 25047 43049 50536925
Renal impairment 74.07 13.22 134 25016 75527 50504447
Inhibitory drug interaction 73.35 13.22 31 25119 2202 50577772
Rheumatoid arthritis 72.58 13.22 8 25142 202542 50377432
Infection susceptibility increased 72.20 13.22 32 25118 2552 50577422
Atrial fibrillation 71.67 13.22 157 24993 101588 50478386
Off label use 69.80 13.22 80 25070 474346 50105628
Impaired quality of life 61.39 13.22 38 25112 6018 50573956
Hyperkalaemia 60.10 13.22 95 25055 47994 50531980
Purpura 57.31 13.22 44 25106 9867 50570107
Glucose tolerance impaired 56.72 13.22 34 25116 5084 50574890
Treatment failure 56.11 13.22 3 25147 137634 50442340
Infusion related reaction 55.25 13.22 9 25141 169548 50410426
Pulmonary oedema 54.81 13.22 92 25058 48846 50531128
Hypotension 53.38 13.22 245 24905 235224 50344750
Death 53.24 13.22 309 24841 325070 50254904
Joint swelling 52.89 13.22 28 25122 245258 50334716
Alopecia 49.92 13.22 30 25120 245017 50334957
Drug intolerance 45.79 13.22 26 25124 219078 50360896
Chronic obstructive pulmonary disease 45.27 13.22 89 25061 53346 50526628
Contraindicated product administered 44.09 13.22 10 25140 148948 50431026
Cellulitis 43.99 13.22 104 25046 70694 50509280
Gastrointestinal haemorrhage 43.72 13.22 106 25044 73215 50506759
Dyspnoea exertional 43.00 13.22 85 25065 51148 50528826
Exposure during pregnancy 42.77 13.22 5 25145 121010 50458964
Therapeutic product effect decreased 42.61 13.22 8 25142 136042 50443932
Arthropathy 40.43 13.22 14 25136 157892 50422082
Bradycardia 39.33 13.22 94 25056 64332 50515642
Cardiac failure acute 37.87 13.22 32 25118 8218 50571756
Hypoxia 37.23 13.22 80 25070 51043 50528931
Left ventricular failure 35.94 13.22 25 25125 4816 50575158
BRASH syndrome 35.59 13.22 10 25140 203 50579771
Hepatic enzyme increased 35.48 13.22 12 25138 137368 50442606
Transfusion 32.54 13.22 36 25114 12869 50567105
Dialysis 32.25 13.22 31 25119 9407 50570567
Respiratory failure 32.07 13.22 109 25041 91072 50488902
Bone density decreased 31.62 13.22 33 25117 11042 50568932
Blood creatinine increased 31.27 13.22 96 25054 76064 50503910
Pleural effusion 30.99 13.22 100 25050 81354 50498620
Congestive cardiomyopathy 30.81 13.22 24 25126 5494 50574480
Pneumonia 29.85 13.22 303 24847 378098 50201876
Arthralgia 29.68 13.22 115 25035 438587 50141387
Epistaxis 29.47 13.22 84 25066 63870 50516104
Acute respiratory failure 29.45 13.22 52 25098 28730 50551244
Haemoglobin decreased 29.23 13.22 133 25017 127083 50452891
Hyperlipidaemia 28.26 13.22 39 25111 17451 50562523
Drug hypersensitivity 27.35 13.22 52 25098 250958 50329016
Gout 27.21 13.22 31 25119 11439 50568535
Blood potassium decreased 25.96 13.22 57 25093 36888 50543086
Anaemia 25.89 13.22 214 24936 252242 50327732
Pain in jaw 25.56 13.22 58 25092 38370 50541604
Poor quality sleep 25.23 13.22 36 25114 16610 50563364
Dehydration 24.98 13.22 145 25005 152304 50427670
Weight increased 24.50 13.22 178 24972 201713 50378261
Musculoskeletal stiffness 24.40 13.22 17 25133 128464 50451510
Therapeutic product effect incomplete 23.61 13.22 8 25142 91507 50488467
Rectal haemorrhage 23.24 13.22 56 25094 38502 50541472
Wound 22.88 13.22 12 25138 105782 50474192
Skin disorder 22.78 13.22 42 25108 23988 50555986
Genital infection female 22.75 13.22 6 25144 95 50579879
Cardiorenal syndrome 22.28 13.22 9 25141 570 50579404
Blood urea increased 22.08 13.22 41 25109 23544 50556430
Oxygen saturation decreased 21.85 13.22 83 25067 73165 50506809
Impaired work ability 21.41 13.22 30 25120 13610 50566364
Discomfort 21.03 13.22 14 25136 108366 50471608
Arteriosclerosis coronary artery 20.46 13.22 22 25128 7614 50572360
Hospitalisation 20.28 13.22 77 25073 67860 50512114
Chronic kidney disease 20.06 13.22 54 25096 39717 50540257
Torsade de pointes 20.04 13.22 27 25123 11808 50568166
Orthopnoea 20.03 13.22 19 25131 5670 50574304
Blood potassium increased 19.93 13.22 32 25118 16366 50563608
Drug abuse 19.88 13.22 3 25147 59843 50520131
Unevaluable event 19.77 13.22 59 25091 46007 50533967
Atrial flutter 19.64 13.22 23 25127 8740 50571234
Abdominal discomfort 19.57 13.22 55 25095 231586 50348388
Chronic left ventricular failure 19.48 13.22 7 25143 321 50579653
Cardiomegaly 19.22 13.22 31 25119 15914 50564060
Intentional overdose 18.88 13.22 4 25146 62500 50517474
Abdominal distension 18.85 13.22 79 25071 72824 50507150
Paracentesis 18.31 13.22 9 25141 907 50579067
Urine output decreased 17.99 13.22 24 25126 10397 50569577
Lactic acidosis 17.54 13.22 46 25104 33309 50546665
Hypersensitivity 17.50 13.22 52 25098 215109 50364865
Sinusitis 17.14 13.22 37 25113 170521 50409453
Product use issue 17.12 13.22 30 25120 149445 50430529
Pain 17.04 13.22 195 24955 578708 50001266
Generalised oedema 16.97 13.22 27 25123 13704 50566270
Oral herpes 16.91 13.22 34 25116 20691 50559283
Diaphragmatic disorder 16.91 13.22 7 25143 472 50579502
Blood aldosterone abnormal 16.68 13.22 4 25146 42 50579932
Asthenia 16.54 13.22 236 24914 318806 50261168
Product use in unapproved indication 16.45 13.22 20 25130 115799 50464175
Suicide attempt 16.28 13.22 3 25147 51729 50528245
Injection site pain 15.95 13.22 19 25131 111005 50468969
Urosepsis 15.89 13.22 28 25122 15437 50564537
Pemphigoid 15.80 13.22 17 25133 5890 50574084
Brain natriuretic peptide increased 15.71 13.22 15 25135 4512 50575462
Liver function test abnormal 15.57 13.22 53 25097 44286 50535688
Blood sodium decreased 15.28 13.22 33 25117 21114 50558860
Lung transplant 15.15 13.22 12 25138 2813 50577161
Claudication of jaw muscles 14.79 13.22 4 25146 70 50579904
Oxygen consumption increased 14.78 13.22 13 25137 3523 50576451
Cardiac arrest 14.63 13.22 81 25069 83570 50496404
Malignant neoplasm progression 14.33 13.22 8 25142 68116 50511858
Rash 14.20 13.22 144 25006 437327 50142647
Compartment syndrome 14.16 13.22 10 25140 1972 50578002
Injection site erythema 14.11 13.22 10 25140 74926 50505048
Incarcerated umbilical hernia 13.99 13.22 3 25147 18 50579956
Infection 13.92 13.22 42 25108 172912 50407062
Unresponsive to stimuli 13.90 13.22 40 25110 30569 50549405
Stomatitis 13.87 13.22 18 25132 101326 50478648
Right ventricular dysfunction 13.80 13.22 9 25141 1559 50578415
Ill-defined disorder 13.71 13.22 5 25145 54649 50525325
Brain stem stroke 13.68 13.22 5 25145 241 50579733
Drug monitoring procedure not performed 13.60 13.22 6 25144 473 50579501
Renal disorder 13.52 13.22 37 25113 27468 50552506
Nasopharyngitis 13.37 13.22 50 25100 192877 50387097
Hypoaesthesia 13.29 13.22 27 25123 127230 50452744
Diuretic therapy 13.23 13.22 4 25146 106 50579868

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 229.78 13.14 536 19660 264731 29289600
Cardiac failure congestive 157.82 13.14 226 19970 76355 29477976
Dyspnoea 111.72 13.14 479 19717 326253 29228078
Cardiac failure 106.94 13.14 193 20003 79094 29475237
Fluid retention 106.37 13.14 104 20092 23456 29530875
Hypervolaemia 85.90 13.14 81 20115 17464 29536867
Pulmonary hypertension 83.72 13.14 82 20114 18526 29535805
Oedema peripheral 65.90 13.14 187 20009 103370 29450961
Pulmonary arterial hypertension 51.78 13.14 42 20154 7407 29546924
Drug ineffective 51.56 13.14 107 20089 363063 29191268
Oedema 45.16 13.14 91 20105 40392 29513939
Venous pressure jugular increased 43.53 13.14 17 20179 712 29553619
Right ventricular failure 41.64 13.14 38 20158 7852 29546479
Renal failure 41.04 13.14 175 20021 118424 29435907
Glomerular filtration rate decreased 38.72 13.14 43 20153 11223 29543108
Hyperkalaemia 38.15 13.14 110 20086 61282 29493049
Blood ketone body increased 38.08 13.14 13 20183 369 29553962
Toxicity to various agents 37.51 13.14 38 20158 173623 29380708
Blood potassium increased 37.31 13.14 48 20148 14603 29539728
Off label use 35.18 13.14 98 20098 300702 29253629
International normalised ratio increased 33.05 13.14 85 20111 44287 29510044
Renal impairment 32.06 13.14 125 20071 81208 29473123
Hypotension 31.67 13.14 234 19962 194120 29360211
Pulmonary oedema 30.94 13.14 81 20115 42654 29511677
Venous pressure jugular decreased 30.73 13.14 7 20189 40 29554291
Febrile neutropenia 29.86 13.14 20 20176 112220 29442111
Gastrointestinal haemorrhage 27.97 13.14 118 20078 79415 29474916
Ventricular tachycardia 27.90 13.14 53 20143 22521 29531810
Pyrexia 26.50 13.14 104 20092 287518 29266813
Cardiac failure chronic 26.31 13.14 27 20169 6440 29547891
Peripheral swelling 25.96 13.14 99 20097 63640 29490691
Hepatic cytolysis 25.54 13.14 30 20166 8317 29546014
Blood pressure systolic decreased 25.30 13.14 21 20175 3823 29550508
Blood creatinine increased 25.22 13.14 120 20076 84982 29469349
Dyspnoea paroxysmal nocturnal 24.59 13.14 14 20182 1380 29552951
Orthopnoea 24.14 13.14 22 20174 4538 29549793
Neutropenia 23.94 13.14 33 20163 131678 29422653
Cardiac failure acute 23.22 13.14 30 20166 9162 29545169
Orthostatic hypotension 21.88 13.14 48 20148 22581 29531750
Vasculitic rash 21.81 13.14 11 20185 850 29553481
Pulmonary renal syndrome 21.65 13.14 7 20189 167 29554164
Dyspnoea exertional 21.33 13.14 64 20132 36426 29517905
Atrial fibrillation 21.21 13.14 134 20062 105512 29448819
Weight increased 21.20 13.14 106 20090 76561 29477770
Dizziness 21.16 13.14 210 19986 189474 29364857
Hepatic cirrhosis 20.49 13.14 36 20160 14408 29539923
Completed suicide 19.16 13.14 20 20176 90226 29464105
Chronic kidney disease 18.64 13.14 61 20135 36355 29517976
Death 17.84 13.14 330 19866 341754 29212577
Anti-neutrophil cytoplasmic antibody positive vasculitis 17.71 13.14 9 20187 707 29553624
Amyloidosis 17.64 13.14 13 20183 1991 29552340
Weight bearing difficulty 16.05 13.14 9 20187 862 29553469
Treatment failure 15.85 13.14 3 20193 36936 29517395
Transitional cell carcinoma 15.80 13.14 12 20184 1923 29552408
Bradycardia 15.57 13.14 87 20109 65542 29488789
Hypovolaemia 15.43 13.14 23 20173 8022 29546309
Reaction to excipient 15.28 13.14 7 20189 437 29553894
Blood urea increased 15.21 13.14 48 20148 28064 29526267
Incarcerated hernia 14.26 13.14 5 20191 154 29554177
Suicide attempt 14.16 13.14 3 20193 34107 29520224
Brain natriuretic peptide abnormal 14.06 13.14 6 20190 316 29554015
Sinus bradycardia 14.04 13.14 27 20169 11576 29542755
Condition aggravated 13.96 13.14 157 20039 146138 29408193
Hospitalisation 13.72 13.14 65 20131 45923 29508408
Abdominal cavity drainage 13.66 13.14 6 20190 339 29553992
Ischaemic cardiomyopathy 13.62 13.14 18 20178 5620 29548711
Haemoglobin decreased 13.55 13.14 123 20073 108252 29446079
Hungry bone syndrome 13.43 13.14 4 20192 72 29554259
Hepatic function abnormal 13.43 13.14 5 20191 39254 29515077
Ascites 13.38 13.14 55 20141 36564 29517767
Dehydration 13.23 13.14 128 20068 114620 29439711
Cardiac death 13.18 13.14 8 20188 888 29553443

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 436.48 12.07 896 38952 448344 64010540
Cardiac failure congestive 327.22 12.07 403 39445 130177 64328707
Fluid retention 245.34 12.07 239 39609 59367 64399517
Hypervolaemia 227.79 12.07 189 39659 38096 64420788
Dyspnoea 227.65 12.07 960 38888 717714 63741170
Cardiac failure 161.97 12.07 292 39556 132081 64326803
Pulmonary hypertension 159.06 12.07 163 39685 42976 64415908
Pulmonary arterial hypertension 154.55 12.07 127 39721 25240 64433644
Right ventricular failure 144.61 12.07 114 39734 21357 64437527
Oedema peripheral 143.67 12.07 366 39482 209951 64248933
Drug ineffective 125.84 12.07 204 39644 840043 63618841
Renal failure 101.75 12.07 294 39554 181394 64277490
Oedema 98.88 12.07 192 39656 91743 64367141
Off label use 95.13 12.07 153 39695 632653 63826231
International normalised ratio increased 93.39 12.07 172 39676 78995 64379889
Hyperkalaemia 91.94 12.07 197 39651 100932 64357952
Body tinea 83.23 12.07 31 39817 1262 64457622
Atrial fibrillation 81.84 12.07 262 39586 170827 64288057
Rheumatoid arthritis 81.57 12.07 5 39843 164289 64294595
Renal impairment 77.98 12.07 221 39627 134796 64324088
Pulmonary oedema 70.04 12.07 152 39696 78522 64380362
Hypotension 69.91 12.07 438 39410 380536 64078348
Infection susceptibility increased 63.92 12.07 32 39816 2694 64456190
Drug abuse 62.88 12.07 5 39843 132369 64326515
Death 60.83 12.07 507 39341 482198 63976686
Bradycardia 59.20 12.07 184 39664 118035 64340849
Gastrointestinal haemorrhage 59.08 12.07 198 39650 132114 64326770
Inhibitory drug interaction 58.01 12.07 33 39815 3594 64455290
Dyspnoea exertional 56.24 12.07 134 39714 73596 64385288
Cardiac failure acute 55.28 12.07 59 39789 16285 64442599
Orthopnoea 54.09 12.07 45 39803 9089 64449795
Treatment failure 53.88 12.07 5 39843 116811 64342073
Infusion related reaction 50.84 12.07 19 39829 164448 64294436
Impaired quality of life 47.13 12.07 36 39812 6435 64452449
Blood creatinine increased 46.13 12.07 186 39662 135596 64323288
BRASH syndrome 43.58 12.07 14 39834 363 64458521
Glucose tolerance impaired 42.92 12.07 34 39814 6409 64452475
Blood potassium increased 41.99 12.07 65 39783 25915 64432969
Dehydration 41.41 12.07 252 39596 216511 64242373
Purpura 41.11 12.07 52 39796 17194 64441690
Intentional overdose 41.08 12.07 4 39844 89940 64368944
Cardiac failure chronic 40.46 12.07 38 39810 9003 64449881
Hypoxia 40.29 12.07 133 39715 88016 64370868
Therapeutic product effect decreased 39.76 12.07 11 39837 115340 64343544
Joint swelling 39.38 12.07 45 39803 215337 64243547
Transfusion 39.36 12.07 52 39796 17942 64440942
Venous pressure jugular increased 39.28 12.07 18 39830 1245 64457639
Drug intolerance 39.25 12.07 35 39813 187957 64270927
Chronic obstructive pulmonary disease 37.81 12.07 113 39735 70935 64387949
Glomerular filtration rate decreased 37.43 12.07 53 39795 19519 64439365
Arthropathy 37.33 12.07 14 39834 120953 64337931
Musculoskeletal stiffness 36.80 12.07 15 39833 123191 64335693
Congestive cardiomyopathy 36.15 12.07 38 39810 10306 64448578
Arthralgia 35.94 12.07 146 39702 442114 64016770
Weight increased 35.79 12.07 240 39608 213108 64245776
Hepatic enzyme increased 35.42 12.07 18 39830 129925 64328959
Left ventricular failure 35.05 12.07 34 39814 8383 64450501
Hospitalisation 34.84 12.07 114 39734 75093 64383791
Febrile neutropenia 34.52 12.07 39 39809 187618 64271266
Blood urea increased 34.47 12.07 81 39767 44072 64414812
Exposure during pregnancy 34.07 12.07 4 39844 77671 64381213
Blood pressure systolic decreased 33.71 12.07 34 39814 8786 64450098
Unevaluable event 33.47 12.07 87 39761 50402 64408482
Acute respiratory failure 33.06 12.07 86 39762 49848 64409036
Alopecia 30.95 12.07 34 39814 165656 64293228
Chronic kidney disease 30.70 12.07 92 39756 57827 64401057
Pyrexia 30.54 12.07 211 39637 558433 63900451
Haemoglobin decreased 30.09 12.07 215 39633 194848 64264036
Product use in unapproved indication 30.05 12.07 39 39809 176579 64282305
Cellulitis 29.98 12.07 126 39722 93531 64365353
Pain in jaw 29.91 12.07 73 39775 40682 64418202
Blood ketone body increased 29.50 12.07 12 39836 620 64458264
Orthostatic hypotension 29.42 12.07 79 39769 46659 64412225
Completed suicide 29.32 12.07 59 39789 224355 64234529
Neutropenia 28.81 12.07 66 39782 239558 64219326
Epistaxis 28.34 12.07 128 39720 98003 64360881
Dialysis 28.28 12.07 43 39805 16877 64442007
Drug hypersensitivity 28.19 12.07 66 39782 237749 64221135
Injection site pain 28.09 12.07 17 39831 111391 64347493
Pleural effusion 27.97 12.07 153 39695 126406 64332478
Bone density decreased 26.94 12.07 32 39816 9920 64448964
Ventricular tachycardia 26.90 12.07 63 39785 34202 64424682
Venous pressure jugular decreased 26.83 12.07 7 39841 84 64458800
Dyspnoea paroxysmal nocturnal 26.19 12.07 16 39832 1988 64456896
Suicide attempt 25.95 12.07 6 39842 71001 64387883
Abdominal distension 24.64 12.07 121 39727 95873 64363011
Gout 24.57 12.07 46 39802 21367 64437517
Cardiorenal syndrome 24.48 12.07 13 39835 1237 64457647
Therapeutic product effect incomplete 24.44 12.07 17 39831 103465 64355419
Pericarditis 23.42 12.07 5 39843 62511 64396373
Genital infection female 23.39 12.07 6 39842 67 64458817
Coma 22.61 12.07 13 39835 87602 64371282
Contraindicated product administered 22.58 12.07 20 39828 107809 64351075
Overdose 22.55 12.07 40 39808 159526 64299358
Malignant neoplasm progression 22.38 12.07 22 39826 112849 64346035
Discomfort 22.34 12.07 11 39837 80867 64378017
Respiratory failure 22.20 12.07 173 39675 161010 64297874
Infection 22.15 12.07 51 39797 184829 64274055
Oxygen consumption increased 21.94 12.07 20 39828 4561 64454323
Right atrial dilatation 21.76 12.07 10 39838 696 64458188
Paracentesis 21.61 12.07 12 39836 1247 64457637
Pneumonia 21.52 12.07 474 39374 559102 63899782
Mucosal inflammation 21.50 12.07 6 39842 62578 64396306
Hypovolaemia 21.28 12.07 36 39812 15450 64443434
Vasculitic rash 21.28 12.07 14 39834 1977 64456907
Toxicity to various agents 20.97 12.07 135 39713 363378 64095506
Injection site erythema 20.53 12.07 9 39839 70791 64388093
Drug monitoring procedure not performed 20.31 12.07 10 39838 812 64458072
Ascites 20.29 12.07 84 39764 61917 64396967
Right ventricular dilatation 20.08 12.07 12 39836 1433 64457451
Seizure 20.02 12.07 46 39802 166846 64292038
Brain natriuretic peptide increased 19.77 12.07 24 39824 7609 64451275
Polyuria 19.55 12.07 31 39817 12612 64446272
Sinusitis 19.36 12.07 38 39810 145890 64312994
Confusional state 19.20 12.07 246 39602 260898 64197986
Rectal haemorrhage 18.87 12.07 82 39766 61735 64397149
Urosepsis 18.87 12.07 42 39806 22052 64436832
Hyperlipidaemia 18.86 12.07 43 39805 22933 64435951
Tricuspid valve incompetence 18.85 12.07 36 39812 16967 64441917
Cardiac murmur 18.78 12.07 29 39819 11534 64447350
Hypoaesthesia 18.65 12.07 36 39812 139072 64319812
Poor quality sleep 18.45 12.07 38 39810 18913 64439971
Abdominal cavity drainage 18.38 12.07 9 39839 722 64458162
Liver function test abnormal 18.29 12.07 79 39769 59322 64399562
Lethargy 18.26 12.07 91 39757 72503 64386381
Generalised oedema 18.21 12.07 40 39808 20813 64438071
Cardiomegaly 18.00 12.07 43 39805 23641 64435243
Blood sodium decreased 17.72 12.07 49 39799 29433 64429451
Cardiogenic shock 17.65 12.07 52 39796 32375 64426509
Aspiration pleural cavity 17.59 12.07 11 39837 1424 64457460
Renal injury 17.52 12.07 33 39815 15396 64443488
Nasopharyngitis 16.99 12.07 63 39785 196010 64262874
Stomatitis 16.85 12.07 26 39822 109579 64349305
Condition aggravated 16.76 12.07 323 39525 372103 64086781
End stage renal disease 16.63 12.07 26 39822 10449 64448435
Blood pressure increased 16.60 12.07 53 39795 172499 64286385
Amyloidosis 16.27 12.07 13 39835 2481 64456403
Arteriosclerosis coronary artery 16.15 12.07 32 39816 15497 64443387
Injection site swelling 16.13 12.07 3 39845 41350 64417534
Multiple sclerosis relapse 16.01 12.07 3 39845 41132 64417752
Urine output decreased 15.98 12.07 33 39815 16459 64442425
Hepatic cytolysis 15.89 12.07 30 39818 14019 64444865
Blood aldosterone abnormal 15.82 12.07 4 39844 42 64458842
Unresponsive to stimuli 15.50 12.07 67 39781 50326 64408558
Neutrophil count decreased 15.36 12.07 15 39833 77181 64381703
Chronic left ventricular failure 15.31 12.07 8 39840 736 64458148
Transitional cell carcinoma 15.26 12.07 12 39836 2237 64456647
Injection site reaction 15.08 12.07 5 39843 46659 64412225
Faeces discoloured 14.71 12.07 42 39806 25687 64433197
Leukopenia 14.64 12.07 25 39823 101217 64357667
Therapeutic response decreased 14.56 12.07 7 39841 52181 64406703
Transplant evaluation 14.38 12.07 10 39838 1547 64457337
Chest pain 14.37 12.07 215 39633 235765 64223119
Suicidal ideation 14.35 12.07 12 39836 66530 64392354
Blood potassium decreased 14.23 12.07 56 39792 40343 64418541
Oxygen saturation decreased 14.18 12.07 114 39734 107062 64351822
Pulmonary renal syndrome 14.18 12.07 7 39841 572 64458312
Peripheral swelling 14.11 12.07 194 39654 208959 64249925
Pain 14.08 12.07 249 39599 553262 63905622
Wound 13.94 12.07 16 39832 76461 64382423
Ischaemic cardiomyopathy 13.79 12.07 19 39829 6819 64452065
Ill-defined disorder 13.75 12.07 5 39843 44047 64414837
Catheterisation cardiac 13.74 12.07 16 39832 4857 64454027
Claudication of jaw muscles 13.67 12.07 4 39844 75 64458809
Hypersensitivity 13.44 12.07 69 39779 196383 64262501
Rash 13.40 12.07 201 39647 458348 64000536
Hepatic function abnormal 13.38 12.07 12 39836 64301 64394583
Generalised tonic-clonic seizure 13.36 12.07 4 39844 39853 64419031
Cardiac disorder 13.36 12.07 69 39779 55747 64403137
Right ventricular dysfunction 13.35 12.07 11 39837 2192 64456692
Palpitations 13.21 12.07 110 39738 104378 64354506
Impaired work ability 13.07 12.07 29 39819 15190 64443694
Cognitive disorder 13.07 12.07 9 39839 55078 64403806
Psoriasis 13.07 12.07 15 39833 71688 64387196
Anaemia 13.04 12.07 316 39532 378364 64080520
Diaphragmatic disorder 12.79 12.07 9 39839 1419 64457465
Atrioventricular block 12.78 12.07 25 39823 11990 64446894
Anhedonia 12.78 12.07 27 39821 13679 64445205
Osteoporosis 12.76 12.07 5 39843 42075 64416809
Oral herpes 12.51 12.07 36 39812 22116 64436768
Myocardial infarction 12.51 12.07 157 39691 165664 64293220
Drug-induced liver injury 12.39 12.07 7 39841 47636 64411248
Hepatic cirrhosis 12.29 12.07 40 39808 26258 64432626
Cardiac arrest 12.11 12.07 147 39701 153917 64304967

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C03CA02 CARDIOVASCULAR SYSTEM
DIURETICS
HIGH-CEILING DIURETICS
Sulfonamides, plain
ATC C03CB02 CARDIOVASCULAR SYSTEM
DIURETICS
HIGH-CEILING DIURETICS
Sulfonamides and potassium in combination
ATC C03EB02 CARDIOVASCULAR SYSTEM
DIURETICS
DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION
High-ceiling diuretics and potassium-sparing agents
FDA PE N0000175366 Increased Diuresis at Loop of Henle
FDA EPC N0000175590 Loop Diuretic
CHEBI has role CHEBI:35498 diuretics
CHEBI has role CHEBI:131770 CFTR inhibitors
MeSH PA D004232 Diuretics
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D045283 Natriuretic Agents
MeSH PA D049994 Sodium Potassium Chloride Symporter Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Edema indication 267038008
Edema due to Hepatic Cirrhosis indication
Peripheral Edema due to Chronic Heart Failure indication
Renal Disease with Edema indication
Pulmonary Edema due to Chronic Heart Failure indication
Hypertensive disorder off-label use 38341003 DOID:10763
Hypercalcemia off-label use 66931009 DOID:12678
Decompensated cardiac failure off-label use 195111005
Anuria contraindication 2472002 DOID:2983
Hypocalcemia contraindication 5291005
Hypovolemia contraindication 28560003
Hyperuricemia contraindication 35885006 DOID:1920
Hypokalemia contraindication 43339004
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Oliguria contraindication 83128009
Hearing disorder contraindication 128540005
Hypomagnesemia contraindication 190855004
Disease of liver contraindication 235856003 DOID:409
Thrombocytopenic disorder contraindication 302215000 DOID:1588




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.36 acidic
pKa2 9.88 acidic
pKa3 0.86 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Solute carrier family 12 member 1 Transporter INHIBITOR Ki 7.60 WOMBAT-PK CHEMBL
Sodium/potassium-transporting ATPase subunit alpha-1 Transporter Kd 7.52 WOMBAT-PK
Solute carrier family 12 member 2 Transporter INHIBITOR IC50 5.60 IUPHAR
G-protein coupled receptor 35 GPCR AGONIST EC50 5.54 IUPHAR

External reference:

IDSource
4017794 VUID
N0000146155 NUI
D00247 KEGG_DRUG
1808 RXNORM
C0006376 UMLSCUI
CHEBI:3213 CHEBI
82U PDB_CHEM_ID
CHEMBL1072 ChEMBL_ID
DB00887 DRUGBANK_ID
D002034 MESH_DESCRIPTOR_UI
2471 PUBCHEM_CID
4837 IUPHAR_LIGAND_ID
2943 INN_ID
0Y2S3XUQ5H UNII
3606 MMSL
4304 MMSL
d00179 MMSL
002312 NDDF
387498005 SNOMEDCT_US
86647004 SNOMEDCT_US
4017794 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 0185-0128 TABLET 0.50 mg ORAL ANDA 21 sections
Bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 0185-0128 TABLET 0.50 mg ORAL ANDA 21 sections
Bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 0185-0129 TABLET 1 mg ORAL ANDA 21 sections
Bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 0185-0129 TABLET 1 mg ORAL ANDA 21 sections
Bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 0185-0130 TABLET 2 mg ORAL ANDA 21 sections
Bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 0185-0130 TABLET 2 mg ORAL ANDA 21 sections
Bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 0409-1412 INJECTION, SOLUTION 0.25 mg INTRAMUSCULAR ANDA 20 sections
bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 0615-8361 TABLET 1 mg ORAL ANDA 20 sections
bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 0615-8362 TABLET 2 mg ORAL ANDA 20 sections
Bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 0615-8393 TABLET 1 mg ORAL ANDA 21 sections
Bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 0615-8394 TABLET 2 mg ORAL ANDA 21 sections
Bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 0641-6007 INJECTION 0.25 mg INTRAMUSCULAR ANDA 22 sections
Bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 0641-6007 INJECTION 0.25 mg INTRAMUSCULAR ANDA 22 sections
Bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 0641-6008 INJECTION 0.25 mg INTRAMUSCULAR ANDA 22 sections
Bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 0641-6008 INJECTION 0.25 mg INTRAMUSCULAR ANDA 22 sections
Bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 0641-6161 INJECTION 0.25 mg INTRAMUSCULAR ANDA 22 sections
Bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 0641-6161 INJECTION 0.25 mg INTRAMUSCULAR ANDA 22 sections
Bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 0641-6162 INJECTION 0.25 mg INTRAMUSCULAR ANDA 22 sections
Bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 0641-6162 INJECTION 0.25 mg INTRAMUSCULAR ANDA 22 sections
Bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 0832-0540 TABLET 0.50 mg ORAL ANDA 22 sections
Bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 0832-0541 TABLET 1 mg ORAL ANDA 22 sections
Bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 0832-0542 TABLET 2 mg ORAL ANDA 22 sections
Bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 0904-7016 TABLET 1 mg ORAL ANDA 21 sections
bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 14539-700 TABLET 0.50 mg ORAL ANDA 19 sections
bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 14539-701 TABLET 1 mg ORAL ANDA 19 sections
bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 14539-702 TABLET 2 mg ORAL ANDA 19 sections
bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 16714-831 TABLET 0.50 mg ORAL ANDA 18 sections
bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 16714-832 TABLET 1 mg ORAL ANDA 18 sections
bumetanide HUMAN PRESCRIPTION DRUG LABEL 1 16714-833 TABLET 2 mg ORAL ANDA 18 sections
Bumex HUMAN PRESCRIPTION DRUG LABEL 1 30698-630 TABLET 0.50 mg ORAL NDA 21 sections